A phase 1/2 study of GB1275, a novel CD11b modulator, as monotherapy and with an anti-PD-1 antibody in specified advanced solid tumors or with chemotherapy in metastatic pancreatic cancer (mPDAC) Meeting Abstract
| Authors: | Bendell, J.; Rasco, D.; Park, W.; Zhou, L.; Galkin, A.; Slee, D.; Carter, L.; Nickle, D.; Tran, R.; Li, J.; Ferguson, B.; Dupont, J.; Gupta, V.; O'Reilly, E. |
| Abstract Title: | A phase 1/2 study of GB1275, a novel CD11b modulator, as monotherapy and with an anti-PD-1 antibody in specified advanced solid tumors or with chemotherapy in metastatic pancreatic cancer (mPDAC) |
| Meeting Title: | 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019) |
| Journal Title: | Journal for ImmunoTherapy of Cancer |
| Volume: | 7 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2019 Nov 6-10 |
| Meeting Location: | National Harbor, MD |
| ISSN: | 2051-1426 |
| Publisher: | Biomed Central Ltd |
| Date Published: | 2019-11-01 |
| Start Page: | 282 |
| Language: | English |
| ACCESSION: | WOS:000496473200839 |
| PROVIDER: | wos |
| PMCID: | PMC6833189 |
| PUBMED: | 31694725 |
| DOI: | 10.1186/s40425-019-0763-1 |
| Notes: | Meeting Abstract: P419 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work